Literature DB >> 2026880

Amino acid residues in the T cell receptor CDR3 determine the antigenic reactivity patterns of insulin-reactive hybridomas.

J Wither1, J Pawling, L Phillips, T Delovitch, N Hozumi.   

Abstract

We examined TCR gene usage in a panel of beef insulin/I-Ad-restricted T cell hybrids obtained from BALB/c mice. These hybrids demonstrated several distinct patterns of reactivity defined by their ability to respond to species variants of insulin. Correlation of TCR-alpha and -beta-gene usage with these patterns of reactivity demonstrated that TCR gene usage was restricted within Ag reactivity groups. In particular, V-J junctional regions (CDR3 equivalent) were restricted with conserved junctional amino acid motifs present in both TCR-alpha- and -beta-chains. Comparison of TCR gene usage in hybrids expressing identical V alpha and V beta gene segments but demonstrating different patterns of reactivity revealed that changes in either J alpha and/or J beta gene segment usage could alter antigenic reactivity. Indeed, single or limited amino acid differences within the CDR3 region were sufficient to markedly alter fine specificity. These data demonstrate the critical role for CDR3 in determining antigenic reactivity in beef insulin-reactive hybrids and are compatible with the current model of TCR/peptide/MHC interaction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2026880

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1992-03-25       Impact factor: 16.971

2.  Characterization of a single-chain T-cell receptor expressed in Escherichia coli.

Authors:  W F Hoo; M J Lacy; L K Denzin; E W Voss; K D Hardman; D M Kranz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

3.  Common T cell receptor clonotype in lacrimal glands and labial salivary glands from patients with Sjögren's syndrome.

Authors:  I Matsumoto; K Tsubota; Y Satake; Y Kita; R Matsumura; H Murata; T Namekawa; K Nishioka; I Iwamoto; Y Saitoh; T Sumida
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

4.  Predicted complementarity determining regions of the T cell antigen receptor determine antigen specificity.

Authors:  C D Katayama; F J Eidelman; A Duncan; F Hooshmand; S M Hedrick
Journal:  EMBO J       Date:  1995-03-01       Impact factor: 11.598

5.  Differential T cell receptor photoaffinity labeling among H-2Kd restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative. Labeling of the alpha-chain correlates with J alpha segment usage.

Authors:  P Romero; J L Casanova; J C Cerottini; J L Maryanski; I F Luescher
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

6.  The somatically generated portion of T cell receptor CDR3α contributes to the MHC allele specificity of the T cell receptor.

Authors:  Philippa Marrack; Sai Harsha Krovi; Daniel Silberman; Janice White; Eleanor Kushnir; Maki Nakayama; James Crooks; Thomas Danhorn; Sonia Leach; Randy Anselment; James Scott-Browne; Laurent Gapin; John Kappler
Journal:  Elife       Date:  2017-11-17       Impact factor: 8.140

7.  Preferential V beta gene usage and lack of junctional sequence conservation among human T cell receptors specific for a tetanus toxin-derived peptide: evidence for a dominant role of a germline-encoded V region in antigen/major histocompatibility complex recognition.

Authors:  B Boitel; M Ermonval; P Panina-Bordignon; R A Mariuzza; A Lanzavecchia; O Acuto
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

8.  Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus.

Authors:  V P Argaet; C W Schmidt; S R Burrows; S L Silins; M G Kurilla; D L Doolan; A Suhrbier; D J Moss; E Kieff; T B Sculley; I S Misko
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.